Online Inquiry

Therapeutic Antibody Development Platforms

Therapeutic antibodies can bind to specific proteins on the cell surface, and more and more therapeutic antibodies are being used in biopharmaceutical research. With a professional technical team and advanced antibody development platform, our company has the capabilities and resources to provide one-stop therapeutic antibody development solutions. Our experts provide you with project support and communication throughout the process to ensure that we can respond quickly to the changing needs of your rare disease therapy research project.

Therapeutic Antibody for Rare Diseases

In 1986, the first therapeutic monoclonal antibody (mAb) was approved. During this period, therapeutic antibody drugs have been rapidly developed. Due to their high specificity and few adverse reactions, antibody drugs are widely used in research in the fields of cancer, autoimmunity, inflammation, and infectious diseases. There are already some cases of therapeutic antibodies being used to treat rare diseases, such as Rituxan is used to treat non-hodgkins lymphoma and Remicade is used to treat Crohn's disease.

2-1-3 Therapeutic Antibody Development Platforms-1Fig.1 Targets for antibody therapeutics approved or in regulatory review globally for diseases. (Wang, Z., et al., 2022)

Technologies for Therapeutic Antibody Development

  • Traditional Animal Immunization Technology
    The antigen is injected into the animal to stimulate B cell differentiation and maturation. The animal serum is collected to isolate and purify the antibody.
  • Hybridoma Technology
    Animals are immunized with antigens, and the collected splenocytes are fused with myeloma cells to produce hybridoma cells that continue to secrete antibodies.
  • Single B Cell Technology
    Single B cell technology utilizes the characteristic that each B cell only produces one specific antibody, amplifying the antibody gene directly from a single B cell to obtain antigen-specific antibodies.
  • Antibody Library Screening Technology
    Phage display technology can clone a large number of antibody gene libraries and select and combine with desired targets. In addition, there are in vitro display technologies represented by ribosome display and mRNA display, and cell surface display technologies represented by yeast display.

Our Services

With a comprehensive array of antibody engineering technologies, such as monoclonal antibody humanization, phage display, single B cell antibody technology, affinity maturation, and the human antibody mouse, as well as antibody application and detection platforms such as western blot, ELISA, flow cytometry and immunohistochemistry, our company provides comprehensive, high-quality, and customizable therapeutic antibody development services.

Polyclonal Antibody Development Platform

Polyclonal antibodies are a heterogeneous mix of antibodies formed by a variety of B cells in the body. Our company is confident to provide customers with polyclonal antibody development services for rare diseases.

Bispecific Antibody (BsAb) Development Platform

Bispecific antibodies are artificial antibodies containing two specific antigen-binding sites. With extensive experience and expertise in cell fusion or recombinant DNA technology, our company provides the production and expression of bispecific antibodies.

Single Domain Antibody Development Platform

Single domain antibodies (sdAb) can selectively bind to specific antigens and are widely used in the development of new drugs and the diagnosis of diseases. With the world's leading technology, our company can immunize various animals such as camels to support the development of sdAb.

Monoclonal Antibody Development Platform

Monoclonal antibodies (mAb) are highly uniform antibodies produced by a single B cell clone and only target a specific antigenic epitope. Over the years, our company has been committed to the construction and improvement of antibody development platforms.

  • mAb Production
  • Recombinant Ab Production
  • Hybridoma Sequencing

Antibody-drug Conjugates Development Platform

Antibody-drug conjugate (ADC) consists of monoclonal antibodies, cytotoxic payloads, and molecular linkers. From ADC preparation to bioanalysis, our company provides end-to-end ADC development services. Our advanced platform can meet any of your needs.

1-3-3-2-2 Quantitative Tissue Distribution Studies-3

Why Choose Us?

  • Ability to customize products and services
  • Providing standardized upstream platform solutions
  • Expertise and experience in the industry
  • High data quality and reliable analysis
  • Economical pricing and fast turnaround time
  • Ph.D.-level scientists and skilled technicians

Project Workflow

2-1-3 Therapeutic Antibody Development Platforms-3

With many years of experience and a proven track record of quality, innovation, and customer support, our company provides comprehensive services for leading and emerging biopharmaceutical companies and scientific research institutions to develop therapeutic antibodies for rare diseases. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.


  • Wang, Z., et al. "Development of therapeutic antibodies for the treatment of diseases." Molecular Biomedicine 3.1 (2022): 35.

For Research Use Only.

Related Services

Copyright © Protheragen. All rights reserves.